Abstract:In the online version of the article titled 'Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma' published in Current Molecular Pharmacology (2024; 2: e18761429290933), a change was made in the author position. [1]. The original article can be found online at: https://www.eurekaselect.com/article/139869 Original: Yunzhi Zhu 1,3,# , Yi Hu 2,# , Chengsheng Yang 1 , Shipu Huang 1 , Jianping Wen 4,# , Weiguo Huang 1,3,# and Shengjun Xiao 1,3,* Corrected: Yunzhi Zhu 1,3,# , Yi Hu 2,# , Chengsheng Yang 1 , Shipu Huang 1 , Jianping Wen 4,* , Weiguo Huang 1,3,* and Shengjun Xiao 1,3,*

Publisher Correction: ‘TRAIL-based gene delivery and therapeutic strategies’ and ‘Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy’

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Publisher Correction: A DNA nanodevice-based vaccine for cancer immunotherapy

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Correction: Highly Penetrative Liposome Nanomedicine Generated by a Biomimetic Strategy for Enhanced Cancer Chemotherapy.

Author Correction: A Next-Generation Tumor-Targeting IL-2 Preferentially Promotes Tumor-Infiltrating CD8+ T-cell Response and Effective Tumor Control

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Corrigendum to: Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma

Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Correction: the Lipogenic LXR-SREBF1 Signaling Pathway Controls Cancer Cell DNA Repair and Apoptosis and is a Vulnerable Point of Malignant Tumors for Cancer Therapy.

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Author Correction: Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells

Correction: Corrigendum: Doxorubicin-loaded Platelets As a Smart Drug Delivery System: an Improved Therapy for Lymphoma

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Author Correction: Suppression of Glioblastoma by a Drug Cocktail Reprogramming Tumor Cells into Neuronal Like Cells

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts: Erratum